R & D outsourcing chemical raw seize export opportunities - chemical raw - the pharmaceutical industries

While the global Financial Crisis is still deepening the spread, but experts analysis, the financial crisis on China Pharmaceutical raw materials Exports, domestic limited impact. Meanwhile, with the introduction of China's medical reform policies, the state created a special implementation of major new drugs, and foreign pharmaceutical companies to expand R & D outsourcing, China API Expected within the favorable export, companies should speed up ready to work together to promote the production of power to a Chinese API manufacturing power shift.

Strong export trend has not changed

Over the years, the rapid development of China's raw material medicine, chemical raw has become the world's largest producer and exporter. According to Customs data, 2008, Chinese Chemical API exports An increase of 29.59 percent, totaling 17.6 billion U.S. dollars, exports to 183 countries and regions.

2009 first quarter, the domestic chemical raw production rose in the face of adversity, the main income of 24.32 billion yuan, up 7.2%. At present, the number of bulk drug exports have gradually picking up, 1 to 4 months than the increase in export volume loop were -4.79%, 6.63%, 39.4% and 3.05%, exports reached 5,094,000,000 U.S. dollars, export prices rose steadily.

Mainly in the development of the global medical industry, it remains an investment in health, international Medicine Although market volatility but no major depression; influenza H1N1 occurred in 2009 Influenza Foreign agents insist on adjustment of development, while reducing the cost of attrition of these companies are more and Environmental protection Pressure increased, more hope from countries such as China and India import bulk drugs.

Industry still needs to enhance strength

Although China claims to pharmaceutical-producing country, exporting country, but not economies of scale. Currently, 63% of small businesses, large enterprises accounted for 15%, and in a "fighting each other" state. From the structure of enterprise property rights, state owned 14%, 44% of the capital stock of private capital, 31%, 10% foreign and Hong Kong, Macao and Taiwan. Guo Zihao large-scale enterprise restructuring lag, compared with the large foreign companies, technology, scale, there are gaps. Although since 2002, the domestic pharmaceutical industry had several waves of mergers and acquisitions wave, some enterprises have financing, but the actual effect, is also limited to the amount of superposition, not a value-added use of capital and resources.

Seize the opportunity to research and development outsourcing

Financial crisis foreign exchange devaluation, the Chinese pharmaceutical raw material price advantage in the affected, the cost of increased competition, falling profits will be negative; the same time exporting country's currency devaluation, resulting in lower customer purchasing power, some products in exports. Nevertheless, China's growth opportunities will more than challenges. Chinese medicine is a special industry, figures from previous years, the global pharmaceutical GDP, GDP growth is 3 to 4 times. International market for pharmaceutical raw materials, production and demand in China will not change, shares can not be replaced, and the export growth in the second half will be new, conservative estimates of its growth is expected to reach 15%.

R & D outsourcing is the long-standing low-copy medical conditions, integration into the global innovation system as soon as possible, by the pharmaceutical powers to important historical opportunity for power. Yu-hung suggested that spawned R & D outsourcing of economic globalization, the financial crisis has accelerated the R & D outsourcing. With the introduction of China's medical reform policies, the state created a special implementation of major new drugs, and because the outbreak of swine influenza H1N1, some countries have to increase our efforts to combat drug purchase, the domestic raw material drug companies must focus on formulating the right strategy to accelerate self-transformation, use of personnel to strengthen the scientific and technological development, new breakthroughs in research and development. Yu Xiong also recommended the development of biopharmaceuticals are currently no generic concept, the EU strongly developed in the United States, increasing the proportion of domestic enterprises to actively keep up with, to provide more security to the domestic pharmaceutical market.

Why You Should Consider Outsourcing For Your Consumer Leads? 4 Essential Things To Understand About Hr Outsourcing Outsource SEO and Reduce Costs Why Outsourcing Your Data Backup Tasks It Outsourcing Companies In India Outsourcing IT: Is Your Company Ready? IT Outsourcing: What It's All About The Benefits Of Outsourcing Your Companys Information Technology Outsource Data Entry is one of the Booming Trend for Data Entry Why You Should Outsource Directory Submission Fragments Of Facts And Benefits Connected With Offshore Call Center Outsourcing Outsource Web Application Developers For Custom Web Application Development Can effective dataentry outsourcing get you high savings?

R & D outsourcing chemical raw seize export opportunities - chemical raw - the pharmaceutical industries